We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Kellogg Company (K - Free Report) has a balanced portfolio of cereal and snack products. Popular brands include Kellogg’s, Keebler, Pop-Tarts, Eggo, Cheez-It, Ready Crust and Kashi.
Kellogg has been struggling to drive sales since 2014 primarily due to weak performance by its cereal products in developed markets as well as soft U.S. snacks businesses owing to lower demand.
Investors should note that earnings estimates for K have moved down by 1 cent to $4.45 per share for 2018 over the past 30 days. However, K has a superb earnings history, with the company delivering positive earnings surprises in three of the past four quarters, thereby bringing the average to a positive earnings surprise of 5.82%.
We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Kellogg reported adjusted EPS of $1.19, beating the Zacks Consensus Estimate of $1.07.
Revenues: Kellogg reported revenues of $3.4 billion, beating the Zacks Consensus Estimate of $3.32 billion.
Key Stats to Note: Organic revenues (excluding the impact of acquisitions, dispositions and foreign exchange) were up 0.6%, as against 1.5% decline in the previous quarter.
Stock Price Movement: Shares were up 3.2% in the pre-market session at the time of writing.
Check back later for our full write up on this K earnings report later!
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Image: Bigstock
Kellogg (K) Q1 Earnings & Revenues Top Estimates
Kellogg Company (K - Free Report) has a balanced portfolio of cereal and snack products. Popular brands include Kellogg’s, Keebler, Pop-Tarts, Eggo, Cheez-It, Ready Crust and Kashi.
Kellogg has been struggling to drive sales since 2014 primarily due to weak performance by its cereal products in developed markets as well as soft U.S. snacks businesses owing to lower demand.
Investors should note that earnings estimates for K have moved down by 1 cent to $4.45 per share for 2018 over the past 30 days. However, K has a superb earnings history, with the company delivering positive earnings surprises in three of the past four quarters, thereby bringing the average to a positive earnings surprise of 5.82%.
Currently, K has a Zacks Rank #3 (Buy), but that could definitely change following Kellogg’s earnings report which was just released. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Kellogg Company Price and EPS Surprise
Kellogg Company Price and EPS Surprise | Kellogg Company Quote
We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Kellogg reported adjusted EPS of $1.19, beating the Zacks Consensus Estimate of $1.07.
Revenues: Kellogg reported revenues of $3.4 billion, beating the Zacks Consensus Estimate of $3.32 billion.
Key Stats to Note: Organic revenues (excluding the impact of acquisitions, dispositions and foreign exchange) were up 0.6%, as against 1.5% decline in the previous quarter.
Stock Price Movement: Shares were up 3.2% in the pre-market session at the time of writing.
Check back later for our full write up on this K earnings report later!
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>